ARCUS BIOSCIENCES INC's ticker is RCUS and the CUSIP is 03969F109. A total of 183 filers reported holding ARCUS BIOSCIENCES INC in Q2 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,681,707 | +51.0% | 205,109 | +70.9% | 0.68% | +59.6% |
Q2 2023 | $2,438,195 | +29.8% | 120,049 | +16.6% | 0.42% | +3.4% |
Q1 2023 | $1,878,483 | +3.9% | 102,987 | +17.8% | 0.41% | -15.1% |
Q4 2022 | $1,808,673 | -49.9% | 87,460 | -36.6% | 0.48% | -53.0% |
Q3 2022 | $3,607,000 | -16.9% | 137,894 | -19.5% | 1.02% | -35.9% |
Q2 2022 | $4,339,000 | -17.8% | 171,214 | +2.3% | 1.60% | +3.4% |
Q1 2022 | $5,281,000 | +11.4% | 167,321 | +42.9% | 1.55% | +47.8% |
Q4 2021 | $4,739,000 | -42.6% | 117,099 | -50.5% | 1.05% | -49.9% |
Q3 2021 | $8,252,000 | +21.8% | 236,637 | -4.1% | 2.09% | +41.0% |
Q2 2021 | $6,773,000 | -23.6% | 246,637 | -21.9% | 1.48% | -28.1% |
Q1 2021 | $8,870,000 | +47.4% | 315,882 | +36.3% | 2.06% | +33.6% |
Q4 2020 | $6,016,000 | +49.3% | 231,758 | -1.4% | 1.54% | +44.4% |
Q3 2020 | $4,029,000 | +1.8% | 235,038 | +46.9% | 1.07% | -4.3% |
Q2 2020 | $3,958,000 | – | 160,000 | – | 1.12% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Invus Financial Advisors, LLC | 1,612,077 | $28,936,782 | 18.14% |
Octagon Capital Advisors LP | 1,968,000 | $35,325,600 | 5.43% |
Decheng Capital Management III (Cayman), LLC | 869,790 | $15,612,731 | 5.21% |
Boxer Capital, LLC | 1,602,200 | $28,759,490 | 1.53% |
SECTORAL ASSET MANAGEMENT INC | 375,456 | $6,739,435 | 1.31% |
DAFNA Capital Management LLC | 222,717 | $3,997,770 | 1.24% |
PFM Health Sciences, LP | 1,405,056 | $25,220,755 | 1.19% |
Ikarian Capital, LLC | 4,000 | $7,180,000 | 0.86% |
Capital Impact Advisors, LLC | 24,280 | $435,826 | 0.73% |
Parkman Healthcare Partners LLC | 205,109 | $3,681,707 | 0.68% |